Doxefazepam
From Wikipedia, the free encyclopedia
 |
|
 |
|
|
Doxefazepam
|
|
| Systematic (IUPAC) name | |
| 9-chloro-6-(2-fluorophenyl)-4-hydroxy -2-(2-hydroxyethyl)-2,5-diazabicyclo [5.4.0]undeca-5,8,10,12-tetraen-3-one |
|
| Identifiers | |
| CAS number | |
| ATC code | N05 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C17H14ClFN2O3 |
| Mol. mass | 348.8 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Hepatic |
| Half life | ? |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Schedule IV(US) |
| Routes | Oral |
Doxefazepam (marketed under brand name Doxans) is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. According to Babbini and colleagues in 1975, this derivative of flurazepam was between 2 and 4 times more potent than the latter while at the same time being half as toxic in laboratory animals.[1]
Doxefazepam is not approved for sale in the United States or Canada.
[edit] References
- ^ Babbini, M.; Torrielli MV, Strumia E, Gaiardi M, Bartoletti M, De Marchi F. (August 1975). "Sedative-hypnotic properties of a new benzodiazepine in comparison with flurazepam. Pharmacological and clinical findings". Arzneimittel-Forschung 25 (8): 1294–1300. PMID 241364.
[edit] External links
|
|||||||||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
